Atossa Therapeutics CEO Steven Quay likely to become NIAID director
read at Endpoints ↗Neutral
Steven Quay, founder and CEO of Atossa Therapeutics, is reported to be the likely choice for director of NIH's National Institute of Allergy and Infectious Diseases.
The report notes his background in clinical-stage biotech and his role at Atossa, but provides no further details about the selection process.
If confirmed, Quay would lead the institute that oversees research on infectious diseases, which could have implications for the biotech sector.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Atossa Therapeutics founder to be selected as NIAID director — report”
read at Endpoints ↗87 words · retrieved Aug 5
comments(0)
5-min edit window · permanent after that